Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab- PLGA microspheres in rabbits

International Journal of Ophthalmology

Volumn 8, Issue 4, 2015, Pages 653-658

  Ye, Zhuo ^a,b   Ji, Yan Li ^a,c   Ma, Xiang ^a   Wen, Jian Guo ^b   Wei, Wei ^a   Huang, Shu Man ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Bevacizumab PLGA microspheres; Immunohistochemistry; Intravitreal injection; Pharmacokinetic; Sustained release

Indexed keywords

EID: 84938575104     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2015.04.02     Document Type: Article

References (25)

1. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26(3):262-269
2. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina2006;26(5):495-511
3. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration:a one-year prospective study. Am J Ophthalmol 2008;145(2):249-256
4. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006;26(8):871-876
5. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26(8):859-870
6. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaeizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36(4):331-335
7. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology2007;114(5):855-859
8. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovasularization secondary to age-related macular degeneration. Retina 2006;26(4):383-390
9. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. Intravitreal bevacizumab(Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695-1705
10. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevaeizumab (Avastin) as treatment for subfoveal choroidal ncovaseularisation secondary to pathological myopia. Br J Ophthalmol 2007;91(2):157-160
11. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microsphere. Adv Drug Deliv Rev 1997;28(1):5-24
12. Noriyuki Kuno, Hinobu Fujii. Recent advances in ocular drug delivery systems. Polymers 2011;3:193-221
13. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009;26(5):1025-1058
14. Chen J, Jin T. Effect of formulation process of sustained-release PLGA microspheres on the protein activity and immunogenicity. Master Thsis, Shanghai Jiao Tong University 2008
15. Spitzer MS, Wallenfels-Thilo B, Sierra A. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006; 90(10):1316-1321
16. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T. Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in Rabbits. Invest Ophthalmol Vis Sci 2009;50(10):4807-4813.
17. Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res2010;27(10):2043-2053
18. Yang R, Chen TN, Chen HL, Wang WJ. Microfabrication of biodegradable (PLGA) honeycomb-structures and potential applications in implantable drug delivery. Sens Actuators B 2005; 106(2):506-551
19. Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evalution of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina 2009;29(5):699-703
20. Martinez-Sancho C, Herrero-Vanrell R, Negro S. Vitamin A palmitate and acyclovir biodegradable microspheres for intraocular sustained release. Int J Pharm 2006;326(1-2):100-106
21. Moshfeghi AA, Peyman GA. Micro-and nanoparticulates. Adv. Drug Delivery Rev 2005;57(14):2047-2052
22. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat Model. J Ocul Pharmacol Ther 2011;27(3):219-224
23. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retinal after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48(6):2814-2823
24. Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localization of intravitreally injected bevacizumab in the anterior chamber angle,iris and ciliary body of the primate eye. Br J Ophthalmol 2008;92(4):541-544
25. Zhang L, Xu JS, Sanders VM, Letson AD, Roberts CJ, Xu RX. Multifunctional microbubbles for image-guided antivascular endothelial growth factor therapy. J Biomed Opt 2010;15(3):1-3